Tezcat Biosciences

Funding and NIH signals

• NIH award NIH awarded $929K (SBIR Phase II 5R44CA265512-03, continuation, notice Aug 27, 2026); 2 NIH awards totaling $1.33M in the last 12 months. NIH RePORTER 5R44CA265512-03 (Aug 27, 2026)
  Evidence (2 events)

  • Aug 27, 2026 · NIH RePORTER 5R44CA265512-03
    Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 5R44CA265512-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 928698; Administering IC: National Cancer Institute; Project title: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 1R41CA306696-01A1
    Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 1R41CA306696-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 399855; Administering IC: National Cancer Institute; Project title: Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals